DHR
Wall Street’s got opinions
Danaher isn’t in the middle of some dramatic takeover, breakup, or scandal. It’s getting the more subtle kind of market-moving attention: analyst ratings. Benzinga says Barclays, Goldman Sachs, and Evercore ISI Group all chimed in between April 6 and April 14, giving Danaher an average price target of $228.33.
Why you should care
For investors, this is less “pop the champagne” and more “the grown-ups in the room still think this thing has room to run.” The implied upside is about 15.11% from those latest calls, which can help put a floor under sentiment when the market starts acting moody.
The catch
This isn’t a fresh earnings beat or a new product launch — it’s a roundup page collecting recent analyst takes. That means the real signal is in the trend, not any single headline:
- Barclays added a fresh view on April 14
- Goldman Sachs followed on April 13
- Evercore ISI Group chimed in on April 6
Danaher also had a prior downgrade back in October 2025, which is a nice reminder that Wall Street can be a bit like a weather app: confident, contradictory, and occasionally wrong.
Big picture: when a steady industrial/healthcare-ish compounder like Danaher keeps showing up on analyst radars with upside attached, traders tend to notice — even if the company itself is just doing its usual quietly excellent thing.